Research & Development

Memorial Sloan Kettering (MSK) Cancer Centre has paired with Absci corporation to develop and discover new novel therapeutics through the use of generative artificial intelligence (genAI).

Using Absci’s Integrated Drug Creation platform, research teams from both corporations will be co-developing therapeutics using genAI for up to six platforms.

Gregory Raskin, MD, senior vice president of Technology Development at MSK stated: “We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”

“By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease,” added Sean McClain, founder and CEO of Absci.

Over the last year, Absci has teamed up with global pharma leaders and other research institutes in efforts to ‘develop novel biologics for debilitating diseases’, according to the press release.

“We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.” said Gregory Raskin.